Function and expression of the proton-coupled amino acid transporter PAT1 along the rat gastrointestinal tract: Implications for intestinal absorption of gaboxadol

British Journal of Pharmacology

Volumn 167, Issue 3, 2012, Pages 654-665

  Broberg, M L ^a   Holm, R ^b   Tonsberg H ^a,b   Frolund S ^a   Ewon, K B ^a,b   Nielsen, A L ^a,b   Brodin, B ^a   Jensen, A ^a   Kall, M A ^b   Christensen, K V ^b   Nielsen, Carsten Uhd ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b H LUNDBECK A S   (Denmark)

Author keywords

colon absorption; gaboxadol; in vivo transporter; PAT1 (SLC36A1); small intestinal absorption; transporter mediated pharmacokinetics

Indexed keywords

AMINO ACID TRANSPORTER; GABOXADOL; MESSENGER RNA; PROLINE; PROTON COUPLED AMINO ACID TRANSPORTER 1; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COLON; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG UPTAKE; DUODENUM; GASTROINTESTINAL TRACT; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; JEJUNUM; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; STOMACH;

ADMINISTRATION, ORAL; AMINO ACID TRANSPORT SYSTEMS; AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CACO-2 CELLS; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL ABSORPTION; ISOXAZOLES; MALE; PROLINE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SYMPORTERS; TRYPTOPHAN; XENOPUS LAEVIS;

EID: 84865996494     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02030.x     Document Type: Article

References (39)

1. Abbot EL, Grenade DS, Kennedy DJ, Gatfield KM, Thwaites DT (2006). Vigabatrin transport across the human intestinal epithelial (Caco-2) brush-border membrane is via the H+-coupled amino-acid transporter hPAT1. Br J Pharmacol 147: 298-306.
2. Alexander S, Harmar A, McGrath I (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164: 1749-1750.
3. Anderson CM, Howard A, Walters JR, Ganapathy V, Thwaites DT (2009). Taurine uptake across the human intestinal brush-border membrane is via two transporters: H+-coupled PAT1 (SLC36A1) and Na+ and Cl- dependent TauT (SLC6A6). J Physiol 587: 731-744.
4. Anderson CMH, Grenade DS, Boll M, Foltz M, Wake KA, Kennedy DJ et al. (2004). H+/Amino acid transporter 1 (PAT1) is the imino acid carrier: an intestinal nutrient/drug transporter in human and rat. Gastroenterology 127: 1410-1422.
5. Boll M, Foltz M, Rubio-Aliaga I, Kottra G, Daniel H (2002). Functional characterization of two novel mammalian electrogenic proton-dependent amino acid cotransporters. J Biol Chem 277: 22966-22973.
6. Center for Drug Evaluation and Research (2006). Guidance for industry: drug interaction studies - study design, data analysis, and implications for dosing and labeling (draft). Food and Drug Administration (FDA).
7. Chen CY, Doong ML, Li CP, Liaw WJ, Lee HF, Chang FY et al. (2010). A novel simultaneous measurement method to assess the influence of intracerebroventricular obestatin on colonic motility and secretion in conscious rats. Peptides 31: 1113-1117.
8. Chen Z, Fei YJ, Anderson CMH, Wake KA, Miyauchi S, Huang W et al. (2003). Structure, function and immunolocalization of a proton-coupled amino acid transporter (hPAT1) in the human intestinal cell line Caco-2. J Physiol 546: 349-361.
9. Choudhuri S, Klaassen CD (2006). Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 25: 231-259.
10. Christensen KV, Leffers H, Watson WP, Sanchez C, Kallunki P, Egebjerg J (2010). Levetiracetam attenuates hippocampal expression of synaptic plasticity-related immediate early and late response genes in amygdala-kindled rats. BMC Neurosci 11: 9.
11. Dobson PD, Kell DB (2008). Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 7: 205-220.
12. Englund G, Rorsman F, Ronnblom A, Karlbom U, Lazorova L, Grasjo J et al. (2006). Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 29: 269-277.
13. European Medicines Agency (2010). Guideline on the investigation of drug interactions (Draft).
14. Foltz M, Mertl M, Dietz V, Boll M, Kottra G, Daniel H (2005). Kinetics of bidirectional H+ and substrate transport by the proton-dependent amino acid symporter PAT1. Biochem J 386: 607-616.
15. Frolund S, Holm R, Brodin B, Nielsen CU (2010a). The proton-coupled amino acid transporter, SLC36A1 (hPAT1), transports Gly-Gly, Gly-Sar and other Gly-Gly mimetics. Br J Pharmacol 161: 589-600.
16. Frolund S, Marquez OC, Larsen M, Brodin B, Nielsen CU (2010b). Delta-aminolevulinic acid is a substrate for the amino acid transporter SLC36A1 (hPAT1). Br J Pharmacol 159: 1339-1353.
17. Frolund S, Rapin N, Nielsen CU (2011). Gaboxadol has affinity for the proton-coupled amino acid transporter 1, SLC36A1 (hPAT1) - a modelling approach to determine IC(50) values of the three ionic species of gaboxadol. Eur J Pharm Sci 42: 192-198.
18. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9: 215-236.
19. Herrera-Ruiz D, Wang Q, Gudmundsson OS, Cook TJ, Smith RL, Faria TN et al. (2001). Spatial expression patterns of peptide transporters in the human and rat gastrointestinal tracts, Caco-2 in vitro cell culture model, and multiple human tissues. AAPS PharmSci 3: E9.
20. Holm R, Kall MA, Frlund S, Nielsen AL, Jensen A, Broberg ML et al. (2012). Rectal absorption of vigabatrin, a substrate of the proton coupled amino acid transporter (PAT1, Slc36a1), in rats. Pharm Res 29: 1134-1142.
21. Howard A, Goodlad RA, Walters JR, Ford D, Hirst BH (2004). Increased expression of specific intestinal amino acid and peptide transporter mRNA in rats fed by TPN is reversed by GLP-2. J Nutr 134: 2957-2964.
22. Kall MA, Fu I, Dige T, Vallano P, Woolf E, Jorgensen M (2007). Development and validation of a selective and sensitive bioanalytical procedure for the quantitative determination of gaboxadol in human plasma employing mixed mode solid phase extraction and hydrophilic interaction liquid chromatography with tandem mass spectroscopic detection. J Chromatogr B Analyt Technol Biomed Life Sci 858: 168-176.
23. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010) NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160:1577-1579.
24. Larsen M, Larsen BB, Frolund B, Nielsen CU (2008). Transport of amino acids and GABA analogues via the human proton-coupled amino acid transporter, hPAT1: characterization of conditions for affinity and transport experiments in Caco-2 cells. Eur J Pharm Sci 35: 86-95.
25. Larsen M, Holm R, Jensen KG, Brodin B, Nielsen CU (2009). Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of L-tryptophan. Br J Pharmacol 157: 1380-1389.
26. Larsen M, Holm R, Jensen KG, Sveigaard C, Brodin B, Nielsen CU (2010). 5-Hydroxy-L-tryptophan alters gaboxadol pharmacokinetics in rats: involvement of PAT1 and rOat1 in gaboxadol absorption and elimination. Eur J Pharm Sci 39: 68-75.
27. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408.
28. McGrath J, Drummond G, Kilkenny C, Wainwright C(2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
29. Metzner L, Kottra G, Neubert K, Daniel H, Brandsch M (2005). Serotonin, L-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1. FASEB J 19: 1468-1473.
30. Naruhashi K, Sai Y, Tamai I, Suzuki N, Tsuji A (2002). PepT1 mRNA expression is induced by starvation and its level correlates with absorptive transport of cefadroxil longitudinally in the rat intestine. Pharm Res 19: 1417-1423.
31. Sai Y (2005). Biochemical and molecular pharmacological aspects of transporters as determinants of drug disposition. Drug Metab Pharmacokinet 20: 91-99.
32. Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ, Reed MW (2000). Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem 285: 194-204.
33. Sugano K, Kansy M, Artursson P, Avdeef A, Bendels S, Di L et al. (2010). Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov 9: 597-614.
34. Tannergren C, Bergendal A, Lennernas H, Abrahamsson B (2009). Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment. Mol Pharm 6: 60-73.
35. Thwaites DT, McEwan GT, Cook MJ, Hirst BH, Simmons NL (1993). H+-coupled (Na+-independent) proline transport in human intestinal (Caco-2) epithelial cell monolayers. FEBS Lett 333: 78-82.
36. Thwaites DT, McEwan GT, Simmons NL (1995). The role of the proton electrochemical gradient in the transepithelial absorption of amino acids by human intestinal Caco-2 cell monolayers. J Membr Biol 145: 245-256.
37. Thwaites DT, Basterfield L, McCleave PM, Carter SM, Simmons NL (2000). Gamma-aminobutyric acid (GABA) transport across human intestinal epithelial (Caco-2) cell monolayers. Br J Pharmacol 129: 457-464.
38. Yuasa H (2008). Drug absorption from the colon in situ. In: Ehrhardt C, Kim KJ (eds). Drug Absorption Studies. Springer US: New York, pp. 77-88.
39. Ziegler TR, Fernandez-Estivariz C, Gu LH, Bazargan N, Umeakunne K, Wallace TM et al. (2002). Distribution of the H+/peptide transporter PepT1 in human intestine: up-regulated expression in the colonic mucosa of patients with short-bowel syndrome. Am J Clin Nutr 75: 922-930.